1Alexander EK, Larsen PR. High dose ( 131 ) I therapy for thetreatment of hyperthyroidism caused by Graves'disease [ J ]. J Clin Endo-crinol Metab, 2002 , 87 : 1073-1077.
3Bahn RS, Burch HB, Cooper DS, et al. Hyperthyroidism and oth-er causes of thyrotoxicosis : Management guidelines of the American thy-roid association and American association of clinical endocrinologists [ J ].Thyroid, 2011,21(6):593-646.
5Allahabadia A, Daykin J, Holder RL, et al. Age and genderpridect the outcome of treatment for Graves hyperthyroidism [ J]. J ClinEndocrinol Metab,2000 , 85(3) : 1038-1042.
7Bossowski A,Czamocka B,Bardadin K,et al.Identification of apoptotic proteins in thyroid gland from patients with Graves' disease and Hashimoto's thyroiditis.Autoimmunity,2008,41:163-173.
8Salmaso C,Bagnasco M,Pesce G,et al.Regulation of apoptosis in endocrine autoimmunity:insights from Hashimoto's thyroiditis and Graves' disease.Ann N Y Acad Sci,2002,966:496-501.
9Rogowski F,Parfienczyk A,Sopotyk A,et al.The value of estimating serum aproptotic marker concentrations in monitoring and prognosis of 131I-therapy in Graves' disease.Nucl Med Rev Cent East Eur,2004,7:117-122.
10Berg GE, Michanek AM, Holmberg EC, et al. lodine- 131 treatment of hyperthyroidism : significance of effective half- life meas- urements [J]. J Nucl Med, 1996, 37 (2): 228-232.
